[1] 张轶伟,杨静.成人代谢综合征和非酒精性脂肪肝病的关系[J].山西医科大学学报,2009,40:341-343.
[2] ALBA L M,LINDOR K.Nonalcoholic fatty liver disease[J].Aliment Pharmacol Ther,2003,17:977-986.
[3] BEDOGNI G,MIGLIOLI L,MASSUTI F,et al.Prevalance of and risk factors for non-alcoholic fatty liver disease:the Dionysos nutrition and liver study[J]. Hepatology,2005,42:44-52.
[4] MALHI H,GORES G J.Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease[J].Semin Liver Dis,2008,28:360-369.
[5] SANYAL A J.Mechanisms of diseas:pathogenesis of nonalcoholic fatty liver disease[J].Nat Clin Pract Gastroenterol Hepatol,2005,2:46-53.
[6] De ALWIS N M,DAY C P.Non-alcoholic fatty liver disease:the mist gradually clear[J].J Hepatol,2008,48:104-112.
[7] FARREL G C,LARTER C Z.Non-alcoholic fatty liver disease:from steatosis to cirrhosis[J].Hepatology,2006,43:99-112.
[8] FAN J G,FARRELL G C.Epidemiology of non-alcoholic fatty liver disease in China [J].J Hepatol,2009,50(1):204-210.
[9] ARGO C K,LOFIA P,CAIDWELL S H,et a1.Statins in liver disease:a molehill,an iceberg,or neither? [J].Hepatology,2008,48:662-669.
[10] JASIFISKA M,OWCZAREK J,ORSZULAK-MICHALAK D.Statins:a new insight into their mechanisms of action and consequent pleiotropic effects[J].Pharmacol Rep,2007,59:483-499.
[11] 杨胜利,薛爱英,刘惠亮.他汀类药物抗炎作用研究进展[J].心血管康复医学杂志,2006,15:409.
[12] THEISE N D,KUWALMRA R.The tissue biology of ductular reactions in human chronic liver disease[J].Gastoenterology,2007,133:350-352.
[13] YANG L,WANG Y,MAO H,et a1.Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells[J].J Hepatol,2008,48:98-106.
[14] 唐怀宇.他汀类药物的不良反应及处理[J].中国实用医药,2008,3:63-64.
[15] ALQAHMNIS A,SANCHEZ W.Statins are safe for the treatment of hypercholesterolemia in patients with chronic liver disease[J].Gastroenterology,2008,135:702-704.
[16] CHALASANI N.Statins and hepatot oxicity:focus on patients with fatty liver[J].Hepatology,2005,41:690-695.
[17] COHEN D E,ANANIA F A,CHALASANI N,et al.An assessment of statin safety by hepatologists[J].Am J Cardiol,2006,97:77-81.
[18] 贾继东,白启轩.非酒精性脂肪性肝病治疗策略[J].临床内科杂志,2008,25:733-735.
[19] ROGLANS N.Atorvastat in treatment induced peroxisome pro-Liferator activated receptor expression and decreased plasma non-esterified fatty acids and liver triglyceride in fructose2fed rats[J].J Pharmacol Exp Ther,2002,302:2321.
[20] 邢象斌,严祥,王玉玲,等.阿托伐他汀治疗高脂血症性脂肪性肝炎的实验性研究[J]. 临床消化病杂志,2004,16:149-151.
[21] 袁雪雯,冯文焕,童国玉,等.阿托伐他汀对高脂饮食大鼠非酒精性脂肪性肝炎的影响[J] 江苏医药,2011,37:1247-1249.
[22] 童国新,王宁夫,陈鹏,等.阿托伐他汀对oxLDL诱导的人单核-巨噬细胞MMP-9和组织因子的影响[J].基础医学与临床,2007,27:178-182.
[23] 金正贤,张延霞,张桂珍.阿托伐他汀对HepG2细胞活性氧及转录因子Sp1mRNA表达的影响[J].中国老年学杂志,2011,31:1611-1612.
[24] 梅蕊.小剂量阿托伐他汀干预治疗对代谢综合征肥胖患者高敏C反应蛋白及血脂的影响[J].疑难病杂志,2011,10:94-95.
[25] KIYICI M,GULTEN M,GUREL S,et al.Ursodeoxycholic acid and atorvastain in the treatment of nonalcoholic steatohepatitis[J].Can J Gastroenterol,2003,17:7131.
[26] GEORGESCU E F,GEORGESCU M.Therapeutic options in non-alcoholic steatohepatitis (NASH).Are all agents alike ? Results of a preliminary study[J].J Gastrointestin Liver Dis,2007,16:167-169.
[27] COMEZ-DOMINGUEZ E.A pilot study of atorvastatin treatment in dyslipemid,non-alcoholic fatty liver patients[J].Aliment Pharmacol Ther,2006,23(11):1643-1647.
[28] 戴禄寿,戴益琛,江拥军,等.阿托伐他汀治疗非酒精性脂肪肝136例疗效分析[J].临床军医杂志,2010,38(5):774.
[29] NAKASHIMA A,OHTWA M,IWASAKI K,et al.Inhibitory effecte of fluvastain and its metabolites on the form at ion of several reactive oxygen species[J].Life Sci 2001,69:1381-1389.
[30] 陈良光,任洁,刘娟.辛伐他汀治疗老年高脂血症280例疗效观察[J].现代医学,2007,35(4):324-325.
[31] 王志蛾,路璐.辛伐他汀对冠心病合并糖尿病患者血脂及胰岛素敏感性的影响[J].山东医药,2004,44:71.
[32] HANEFELD M,MARX N,PTVTZNER A,et al.Anti-inflammatory effects of p ioglitazone and /or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein:the PIOSTAT study[J].J Am Coll Cardiol,2007,49:290-297.
[33] TANDON V,BANO G,KHAJURIA V,et al.Pleiotropic effects of statins[J].Indian J Pharmacol,2005,37:77-85.
[34] 阎明,吕瑞娟,贾晓青,等.辛伐他汀对高脂血症性脂肪肝治疗的实验研究[J].中华消化杂志,2002,22:27-29.
[35] 郭宏华,李宏宇.辛伐他汀治疗非酒精性脂肪性肝病的临床研究[J].临床内科杂志,2006,23:6411.
[36] ZAFRA C,ABRALDES J G,TURNES J,et al.Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis [J].Gastroenterology,2004,126:749-755.
[37] 詹海勇,黄聪武.辛伐他汀对腹型肥胖患者NAFLD发病率的影响及其机制[J].中国医药指南,2011,91:82-183.
[38] 徐明,孙申,冯盼盼,等.辛伐他汀对大鼠肝纤维化的影响及其作用机制[J].科技导报,2010,24:89-92.
[39] 徐明,孙申,冯盼盼,等.辛伐他汀对肝纤维化大鼠Ⅳ-C、MMP-2及TIMP-2表达的影响[J].山东医药,2010,50:38-39.
[40] ROMBOUTS K,KISANGA E,HELLEMANS K,et al.Effect of HMG-CoA reductase inhib-itors on proliferation and protein synthes is by rat hepatic stellate cells[J].J Hepatol,2003,38:564-572.
[41] 蒋国军,张黎,李铁军,等.洛伐他汀对氧化修饰低密度脂蛋白刺激U937细胞缺氧诱导因子-1α表达的影响[J].药学实践杂志,2009,27:170-173.
[42] 郑高利,龚维桂,陈珏,等.洛伐他汀降血脂作用的研究[J].现代应用药学,1997,14:3-5.
[43] 尹建梅,王霁云,王红,等.洛伐他汀调治糖尿病合并脂代谢紊乱的临床研究[J].中国慢性病预防与控制,2004,12:37-38.
[44] 黄照河,陆克兴,李天资,等.壮族高血压患者胰岛素抵抗和洛伐他汀的干预研究[J]. 右江民族医学院学报,2008,30(6):925-927.
[45] 陈晓平,黄德嘉,黄明慧,等.洛伐他汀对ⅡB型高脂血症患者血脂、血糖及胰岛素代谢的影响[J].华西医科大学学报,1999,30:444-445.
[46] 张晓兰,张志钢,闻勤生.氟伐他汀对非酒精性脂肪性肝炎的治疗作用[J].肝脏,2009,14:47-48.
[47] 李俐,金生荣.氟伐他汀对小鼠肝脏胶原纤维形成的抑制作用[J].中国校医,2003,17:410-411.
[48] 李旭东,黄勇先,钱中良,等.短期服用氟伐他汀对血脂及C反应蛋白的影响[J].感染.炎症.修复,2004,5:155-157.
[49] 羊镇宇,薄小萍,朱剑秋.氟伐他汀对高胆固醇血症患者血小板活化功能及胰岛素抵抗的影响[J].中华心血管病杂志,2000,28:264-266.
[50] 寿锡凌,贾中慧,陈新义,等.冠心病患者降脂治疗对血浆内皮素及胰岛素抵抗的影响[J].中国循环杂志,1998,13:137-139. |
